IODINE I 131 APAMISTAMAB

Summary

Iodine I 131 Apamistamab (CHEMBL4297997) is a phase-3 clinical-stage antibody (ATC V10XA04); indicated across 2 conditions including acute myeloid leukemia and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: V10XA04
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297997
Name	IODINE I 131 APAMISTAMAB
Type	Antibody
Max phase	3
ATC	V10XA04

Also known as: Apamistamab iodine i-131, I 131 moab bc8, I-131 moab bc8, Iodine (131i) apamistamab, Iodine i 131 apamistamab, Iodine i-131 apamistamab, Iodo (131i) apamistamab, Iomab-b, IOMABB, Iomab-B, IODINE I 131 APAMISTAMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02665065	PHASE3	ACTIVE_NOT_RECRUITING	Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
NCT06768905	PHASE1/PHASE2	RECRUITING	IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).